Zydus reported positive Phase II(b) trial results for Saroglitazar Mg in MASH.

Zydus Lifesciences LimitedZYDUSLIFE · Filed with the exchange

The study met its primary endpoint, showing resolution of steatohepatitis without worsening fibrosis, marking a key milestone for this significant unmet global health need.

Read the original filing(PDF)

No comments yet. Be the first.

More from Zydus Lifesciences Limited

All announcements

Credit Ratings11-09-2026
Credit Rating
Investor Meet11-09-2026
Analysts/Institutional Investor Meet/Con. Call Updates
Others09-09-2026
Copy of Newspaper Publication
Updates05-09-2026
General Updates
Updates01-09-2026
General Updates
Updates26-08-2026
General Updates

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.